Pre-made Tepoditamab biosimilar ( Bispecific mAb, anti-CLEC12A;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-563
Anti-CLEC12A;CD3E therapeutic antibody (Pre-made Tepoditamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tepoditamab (formerly MCLA 117) a bispecific, human IgG antibody (with a silenced region), is being developed by Merus for the treatment of acute myeloid.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CLEC12A;CD3E therapeutic antibody (Pre-made Tepoditamab biosimilar,Bispecific mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Companies||Genmab;Janssen Research & Development|
|Conditions Active||Acute myeloid leukaemia;Myelodysplastic syndromes|